Imlunestrant (LY-3484356) is an orally active, potent and selective estrogen receptor degrader (SERD) with pure antagonistic properties. Imlunestrant results in sustained inhibition of ER-dependent gene transcription and cell growth. Imlunestrant can be used for the research of ER-positive (ER+) advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC). In Vitro LY3484356 shows favorable pharmacokinetic (PK) properties, including antitumor activity in ESR1 mutants. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid